Contract sales-force provider PDI said that its fee-for-service agreements with AstraZeneca would be terminated effective April 30. The termination affects approximately 800 field representatives. The revenue impact is projected to be approximately $65 million to $70 million in 2006, PDI said. “We have worked with AstraZeneca for over 12 years and look forward to creating future business opportunities with them. We are vigorously exploring potential opportunities to redeploy these high performing sales teams,” said PDI’s president Steven Budd in a statement.
AstraZeneca ends contract sales agreement with PDI
Contract sales-force provider PDI said that its fee-for-service agreements with AstraZeneca would be terminated effective April 30. The termination affects approximately 800 field representatives.
